The Injectable Drug Delivery Devices Market is a pivotal segment in the healthcare industry, dedicated to the development and utilization of devices for the administration of pharmaceuticals through injectable routes. This market encompasses a variety of devices, including pre-filled syringes, autoinjectors, and needle-free injectors, offering precise and convenient delivery of medications. Key components involve advancements in device design, safety features, and the increasing prevalence of chronic diseases requiring injectable therapies.
Major drivers of the Injectable Drug Delivery Devices Market include the growing demand for self-administration of drugs, advancements in biologics and specialty drugs, and the emphasis on patient-centric care. These devices provide benefits such as improved adherence to treatment regimens, reduced healthcare costs, and minimized needlestick injuries for healthcare providers.
Challenges involve regulatory considerations, ensuring device compatibility with diverse drug formulations, and addressing patient concerns related to injections. Geographically, North America and Europe lead in market share due to well-established healthcare infrastructures, while Asia-Pacific is witnessing significant growth with increasing healthcare awareness and accessibility. As the Injectable Drug Delivery Devices Market continues to advance, it remains instrumental in shaping the landscape of drug administration, providing innovative solutions for improved patient outcomes and enhanced therapeutic experiences.
The global injectable drug delivery devices market is to record 11.5% CAGR owing to its ease of application during the forecast period (2018-2023). Market Research Future (MRFR) in their latest report on the injectable drug delivery devices market claimed that the market could achieve such a feat. Injectable drug delivery devices are tools that helps in effective drug delivery into the body and creates an opportunity for the drug to work quickly.
The injectable drug delivery devices market is expected to receive substantial market traction due to the sleek designs and simplicity in application. Other than these factors, the market can gain more from rapidly increasing FDA approval of new products. Its being self-injectable is making it easier for several patients to take up these tools and keep their disease in check. These factors are for sure to trigger the global injectable drug delivery devices market.
Competitive Landscape:
The global injectable drug delivery devices market players is thriving owing to the active participation from many of the market leaders such as Antares Pharma, AstraZeneca, Eisai Co., Ltd., Becton, Dickinson and Company, Eli Lilly and Company, Pfizer Inc., F.Hoffmann-La Roche AG, Mylan N.V., Johnson & Johnson Services Inc., Novo Nordisk, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, and Inovio Pharmaceuticals Inc.
Segmental Analysis:
MRFR in their last report on the global injectable drug delivery devices market segmented the said market on the grounds of devices, therapeutic application, usage pattern, site of delivery, distribution channel, and facility of use.
By devices, the injectable drug delivery devices market comprises conventional injection devices and self-injection devices. The conventional injection devices segment is leading the injectable drug delivery devices market and it has been sub-segmented into material, product, and utility. The self-injectable devices segment includes needle-free injectors, pen systems and autoinjectors.
By therapeutic application, the injectable drug delivery devices market can be segmented into autoimmune diseases, hormonal disorders, cancer, and others. The autoimmune diseases segment is helming the global injectable drug delivery devices market with an expected market valuation USD 19,913.7 Mn by 2023.
By usage pattern, the injectable drug delivery devices market includes curative and immunization. The curative segment is anticipated to project the fastest CAGR over the review period.
By site of delivery, the injectable drug delivery devices market comprises intramuscular, subcutaneous, and intradermal. The intramuscular segment tops the global injectable drug delivery devices market.
By distribution channel, the injectable drug delivery devices market consists hospital & retail pharmacies and online platforms. The hospitals & retail pharmacies segment has the maximum global share. The online platform segment can display the fastest CAGR of 11.4% during the assessment period.
Based on the facility of use, the injectable drug delivery devices market includes hospitals and clinics, home care settings, and others. The home care settings segment is attaining substantial growth.
Regional Analysis:
MRFR, based on their detailed study of the global injectable drug delivery devices market, segmented it into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The global market has the Americas on the top and the valuation could reach a substantial USD 17,401.8 million during the assessment period. The market would also a mark an attainment of 11.3% CAGR. The market is bound to receive substantial traction from the expansion of biotechnological industry. Rising cases of diabetes and cancer, and high healthcare expenditure are majorly propelling the expansion of the injectable drug delivery devices market in this region.
Europe stands second as per the reports in the year 2017 and is expected to surpass USD 13,074.3 Mn by the end of 2023 at a CAGR of 11.2%. Technologically advanced healthcare solution is getting implemented all around in the region owing to high investment in research and development sector.
The APAC market is deemed to be the fastest growing region which can exhibit CAGR of 11.4% during the forecast period. The region would substantially help end-users with cost-effective prices and the huge population is expected to lure in big players which would help the market in expansion. However, the MEA market can expect only a steady growth as lack of knowledge of such devices and presence of poor economies have the potential to jeopardize the predicted growth rate.
Related Reports:
Biosimilar Contract Manufacturing
Nuclear Magnetic Resonance Spectroscopy
For more information visit at MarketResearchFuture
Comments (0)